CSCIF Stock Financial Analysis - COSCIENS Biopharma Inc. (OTCPK) Stock

Overview

Aeterna Zentaris Inc., a biopharmaceutical company based in Canada, primarily engages in developing and commercializing novel therapeutics and diagnostic tests. The company has a focused commitment to hormone health and aims to advance therapeutic options for conditions related to growth hormone deficiencies. A key project includes Macrilen (macimorelin), an orally active ghrelin agonist used for the diagnosis of adult growth hormone deficiency, which showcases the company's pioneering approach in addressing niche medical needs with innovative solutions. Additionally, Aeterna Zentaris is involved in various stages of clinical and preclinical development of other new diagnostic and therapeutic products, further underscoring its role in enhancing patient care through targeted medical interventions.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for COSCIENS Biopharma Inc. as of June 30, 2025 is 9.44 MM.
The operating income for COSCIENS Biopharma Inc. as of June 30, 2025 is -10.33 MM.
The net income for COSCIENS Biopharma Inc. as of June 30, 2025 is -18.84 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30	9.44	-10.33	-18.84
2025-03-31	9.03	-11.74	-17.56
2024-12-31	9.59	-9.94	-15.31
2024-09-30	4.83	-21.75	-23.21
2024-06-30	7.56	-8.73	-5.16
2024-03-31	6.62	-6.08	-4.60
2023-12-31	7.14	-4.63	-3.48
2023-09-30	6.46	-10.16	-17.74
2023-06-30	8.32	-9.33	-17.02
2023-03-31	6.71	-12.93	-20.37
2022-12-31	14.57	4.32	3.45
2022-09-30	4.11	-14.38	-13.17
2022-06-30	3.30	-12.71	-11.68
2022-03-31	5.11	-10.15	-9.55
2021-12-31	5.26	-8.67	-8.37
2021-09-30	6.67	-6.79	-6.79
2021-06-30	5.75	-6.48	-5.99
2021-03-31	4.23	-5.79	-7.36
2020-12-31	3.65	-5.92	-5.12
2020-09-30	1.30	-6.96	-4.81

Income Statement: EPS

The earnings per share basic for COSCIENS Biopharma Inc. as of June 30, 2025 is -5.98.
The earnings per share diluted for COSCIENS Biopharma Inc. as of June 30, 2025 is -5.98.

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30	-5.98	-5.98
2025-03-31	-6.04	-6.04
2024-12-31	-5.93	-5.93
2024-09-30	-14.28	-14.28
2024-06-30	-2.66	-2.66
2024-03-31	-2.49	-2.49
2023-12-31	-1.89	-1.89
2023-09-30	-11.59	-11.59
2023-06-30	-11.12	-11.12
2023-03-31	-14.85	-14.85
2022-12-31	1.87	1.86
2022-09-30	-10.85	-10.86
2022-06-30	-9.62	-9.61
2022-03-31	-7.87	-7.49
2021-12-31	-7.28
2021-09-30	-6.77	-6.65
2021-06-30	-7.13	-6.88
2021-03-31	-12.35	-12.95
2020-12-31	-12.46
2020-09-30	-15.84	-15.41

Cash Flow: Operations, Investing, Financing

The cash from operating activities for COSCIENS Biopharma Inc. as of June 30, 2025 is -17.11 MM.
The cash from investing activities for COSCIENS Biopharma Inc. as of June 30, 2025 is -0.90 MM.
The cash from financing activities for COSCIENS Biopharma Inc. as of June 30, 2025 is -0.70 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	-17.11	-0.90	-0.70
2025-03-31	-14.07	25.03	-0.69
2024-12-31	-14.57	25.08	-0.59
2024-09-30	-27.19	26.06	-0.34
2024-06-30	-4.73	24.67	-0.42
2024-03-31	-4.13	-1.26	-0.39
2023-12-31	-2.58	-0.73	-0.36
2023-09-30	-8.45	-0.05	-0.18
2023-06-30	-9.01	-0.05	-0.18
2023-03-31	-13.05	-0.04	-0.15
2022-12-31	5.23	-0.30	-0.27
2022-09-30	-12.67	-0.18	0.01
2022-06-30	-10.21	-0.20	0.01
2022-03-31	-9.00	-0.16	0.07
2021-12-31	-8.58	-0.66	51.04
2021-09-30	-3.65	-0.53	50.91
2021-06-30	-3.96	-0.51	67.73
2021-03-31	-2.73	-0.45	67.66
2020-12-31	-4.13	0.06	20.47
2020-09-30	-9.60	0.06	20.32

Valuation Metrics : PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30

Management Effectiveness

The roa for COSCIENS Biopharma Inc. as of June 30, 2025 is -0.38.
The roe for COSCIENS Biopharma Inc. as of June 30, 2025 is -0.72.
The roic for COSCIENS Biopharma Inc. as of June 30, 2025 is -2.01.
The croic for COSCIENS Biopharma Inc. as of June 30, 2025 is -1.97.
The ocroic for COSCIENS Biopharma Inc. as of June 30, 2025 is -1.83.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	-0.38	-0.72	-2.01	-1.97	-1.83
2025-03-31	-0.55	-1.35	-1.42	0.83	-1.14
2024-12-31	-0.41	-0.84	-0.99	0.63	-0.94
2024-09-30	-0.55	-0.88	-1.07	-0.07	-1.26
2024-06-30	-0.35	-0.58	-1.37	-1.29	-1.31
2024-03-31	-0.30	-0.46	-0.90	-0.90	-0.93
2023-12-31	-0.35	-0.47	-0.88	-0.57	-0.57
2023-09-30	-0.32	-0.42	-0.77	-0.54	-0.54
2023-06-30	-0.32	-0.42	-0.77	-0.54	-0.54
2023-03-31	-0.32	-0.46	-0.77	-0.54	-0.52
2022-12-31	-0.16	-0.22	-0.27	-0.29	-0.26
2022-09-30	-0.16	-0.22	-0.27	-0.29	-0.26
2022-06-30	-0.14	-0.19	-0.21	-0.22	-0.19
2022-03-31	-0.11	-0.15	-0.18	-0.18	-0.17
2021-12-31	-0.23	-0.63	-0.16	0.77	-0.16
2021-09-30	-0.20	-0.43	-0.11	0.77	-0.06
2021-06-30	-0.34	-6.37	-0.10	1.03	-0.06
2021-03-31	-0.37	-4.35	-0.11	1.00	-0.04
2020-12-31	-0.26		-0.38	1.23	-0.31
2020-09-30	-0.22		-0.31	0.71	-0.63

Gross Margins

The gross margin for COSCIENS Biopharma Inc. as of June 30, 2025 is 0.47.
The net margin for COSCIENS Biopharma Inc. as of June 30, 2025 is -2.00.
The operating margin for COSCIENS Biopharma Inc. as of June 30, 2025 is -1.09.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30	0.47	-2.00	-1.09
2025-03-31	0.47	-1.94	-1.30
2024-12-31	0.49	-1.60	-1.04
2024-09-30	0.86	-4.80	-4.50
2024-06-30	0.91	-7.60	-8.39
2024-03-31	0.95	-3.68	-4.00
2023-12-31	0.97	-3.41	-2.29
2023-09-30	0.97	-2.60	-1.71
2023-06-30	0.97	-2.60	-1.71
2023-03-31	0.98	-3.89	-2.68
2022-12-31	0.97	-3.20	-3.50
2022-09-30	0.97	-3.20	-3.50
2022-06-30	0.96	-3.54	-3.85
2022-03-31	0.97	-1.87	-1.99
2021-12-31	0.98	-1.59	-1.65
2021-09-30	0.64	-1.56	-1.56
2021-06-30	0.60	-1.61	-1.74
2021-03-31	0.53	-2.33	-1.84
2020-12-31	0.37	-1.40	-1.62
2020-09-30	0.07	-3.69	-5.34

DE:ET8
GB:0UGB
CA:CSCI	CA$3.45